Sarclisa® (isatuximab-irfc) – New indication
September 20, 2024 - Sanofi announced the FDA approval of Sarclisa (isatuximab-irfc), in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).